BioSpace News Archive

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences.

AVITA Medical, Inc. is pleased to announce that the RECELL® System won Best Product for the second year in a row at the Annual Meeting of the American Association for the Surgery of Trauma.

Prostate cancer management reached a new pinnacle of precision with Bot Image’s ProstatID using Bi-parametric MRI (bpMRI).

UPPI, LLC and Evergreen Theragnostics, Inc. , announced their agreement allowing UPPI participating pharmacies to prepare, sell, and distribute Octevy™ (Kit for Preparation of Ga 68 DOTATOC Injection), if approved by the United States Food & Drug Administration (FDA), to PET customers across the country.

Longhorn Vaccines and Diagnostics today presented new data from an animal study showing that LHNVD-201, the company’s unconjugated peptide vaccine candidate, generated broad and durable neutralizing antibodies against Covid-19 and influenza viruses. Study results were presented at the 17th Vaccine Congress, taking place in Glasgow, Scotland from September 24-27, 2023.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the Chardan 7th Annual Genetic Medicines Conference in New York City on Monday, October 2, 2023.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company’s gene therapy and auditory programs.

Inovalon today announced that its annual Customer Congress will take place from October 15-17, 2023 in Washington, D.C.

Passage Bio, Inc. today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines Conference on Monday, October 2, 2023 at 5:00 p.m ET.

Cara Therapeutics, Inc. today announced that its licensing partner Maruishi Pharmaceutical Co., Ltd. received manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare for KORSUVA ® IV Injection Syringe for the treatment of pruritus in hemodialysis patients.